Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis

被引:22
|
作者
Scamuffa, Nathalie [1 ,2 ]
Sfaxi, Fatma [1 ,2 ]
Ma, Jia [1 ,2 ]
Lalou, Claude [1 ,2 ]
Seidah, Nabil [3 ]
Calvo, Fabien [4 ]
Khatib, Abdel-Majid [1 ,2 ]
机构
[1] Univ Bordeaux 1, Angiogenesis Lab, F-33405 Talence, France
[2] INSERM, UMR 1029, F-33400 Talence, France
[3] Univ Montreal, Clin Res Inst Montreal IRCM, Lab Biochem Neuroendocrinol, Montreal, PQ, Canada
[4] Univ Paris 07, INSERM, UMRS 940, Inst Genet Mol, Paris, France
关键词
CELLS MALIGNANT PHENOTYPES; COLON-CARCINOMA CELLS; CANCER; GROWTH; INHIBITION; RECEPTOR; TUMORIGENICITY; INVASIVENESS; PROSEGMENTS; REPRESSES;
D O I
10.1093/carcin/bgt345
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Proteolytic maturation of various precursor proteins by the proprotein convertase Furin is now considered as a crucial step in tumor progression and metastasis. Here, we report the repression of the malignant and metastatic potential of carcinoma cells by the prodomain region of Furin (ppFurin), a naturally occurring inhibitor of this convertase. Overexpression of ppFurin in carcinoma cells in a stable manner significantly reduced their convertase activity and ability to mediate processing of the Furin cancer-related substrates platelet-derived growth factor (PDGF)-A and insulin-like growth factor-I receptor precursors. Unprocessed platelet-derived growth factor-A produced by ppFurin expressing cells failed to induce the activation of Akt in the platelet-derived growth factor receptor-expressing cells NIH BALB/c-3T3 and treatment of ppFurin expressing cells with insulin-like growth factor-I failed to induce Akt phosphorylation, compared with controls. The malignant potential of ppFurin expressing cells was significantly reduced as revealed by the loss of anchorage-independent growth and survival that associated their increased chemosensitivity. In vivo, comparative studies revealed that expression of ppFurin in the carcinoma cells MDA-MB-231 and CT-26 cells inhibited tumor growth when subcutaneously inoculated in nude mice. The use of an experimental liver colorectal metastasis model revealed the reduced ability of metastatic carcinoma CT-26 cells to colonize the liver in response to intrasplenic/portal inoculation. Further analyses revealed reduced Furin activity in tumors derived from intrasplenic inoculated mice with ppFurin expressing CT-26 cells. This finding highlights the role of Furin in the malignant and metastatic potential of tumor cells and suggests the possible consideration of using its naturally occurring inhibitor ppFurin in anticancer therapy.
引用
收藏
页码:528 / 536
页数:9
相关论文
共 50 条
  • [41] Regulation of proprotein convertase subtilisin/kexin type 9: Therapeutical perspectives
    Chan, Dick C.
    ATHEROSCLEROSIS, 2011, 217 (01) : 77 - 79
  • [42] PROPROTEIN CONVERTASE SUBTILISIN/ KEXIN TYPE 9 LEVELS AND ARTERIAL FUNCTION
    Koutagiar, I.
    Vlachopoulos, C.
    Terentes-Printzios, D.
    Skoumas, J.
    Skliros, N.
    Rigatou, A.
    Ioakeimidis, N.
    Pantou, S.
    Georgakopoulos, C.
    Miliou, A.
    Tousoulis, D.
    ATHEROSCLEROSIS, 2018, 275 : E132 - E132
  • [43] Proprotein convertase models based on the crystal structures of furin and kexin: Explanation of their specificity
    Henrich, S
    Lindberg, I
    Bode, W
    Than, ME
    JOURNAL OF MOLECULAR BIOLOGY, 2005, 345 (02) : 211 - 227
  • [44] Therapeutic Potential Of The Proprotein Convertase Subtilisin/Kexin ( PCSK) Family In Vascular Disease
    Suur, Bianca E.
    Chemaly, Melody
    Liljeqvist, Moritz Lindquist
    Djordjevic, Djordje
    Stenemo, Markus
    Bergman, Otto
    Karlof, Eva
    Lengquist, Mariette
    Odeberg, Jacob
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2022, 42
  • [45] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
  • [46] The Role of Proprotein Convertase Subtilisin/Kexin Type 9 in HyperlipidemiaFocus on Therapeutic Implications
    Michel Farnier
    American Journal of Cardiovascular Drugs, 2011, 11 : 145 - 152
  • [47] PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Goes "DAMP"
    Silverstein, Roy L.
    CIRCULATION, 2021, 143 (01) : 62 - 64
  • [48] The role of proprotein convertase subtilisin/kexin type 9 inhibitors in clinical practice
    Blanquez Martinez, David
    Hayon Ponce, Maria
    Caballero Romero, Alvaro
    Nieto Gomez, Pelayo
    Diaz Villamarin, Xando
    Alvarez Sanchez, Raquel
    Cabeza Barrera, Jose
    Davila Fajardo, Cristina
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (01) : 302 - 302
  • [49] The Promise of Proprotein Convertase Subtilisin/Kexin 9 Inhibitors for the Treatment of Familial Hypercholesterolemia
    Pokharel, Yashashwi
    Virani, Salim S.
    Ballantyne, Christie M.
    CURRENT ATHEROSCLEROSIS REPORTS, 2015, 17 (05)
  • [50] Statins Induce Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9
    Lagace, Thomas A.
    Bashmakov, Yuriy
    Anderson, Norma N.
    McNutt, Markey C.
    Grefhorst, Aldo
    Ho, Y. K.
    Horton, Jay D.
    FASEB JOURNAL, 2008, 22